Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Kilbanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785–795.
Bellantoni M. Approach to the diagnosis and management of the elderly patient. In Kelley’s Textbook of Internal Medicine. HD Humes (ed). Philadelphia: Lippincott Williams & Wilkins, 2000.
Tosteson ANA. Economic impact of fractures. In Osteoporosis in Men: The Effects of Gender on Skeletal Health. ES Orwell (ed). San Diego: Academic Press, 1999:15–27.
U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, 2004.
Byers PH. Disorders of collagen biosynthesis and structure. In The Metabolic and Molecular Bases of Inherited Disease, 8th Ed. C Scriver, AL Beaudet, WA Sly, et al (eds). New York: McGraw-Hill, 2001:5241–5285.
Favus MJe. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research, 2003.
Welten DC, Kemper HCG, Post GB, et al. Relative validity of 16-year recall of calcium intake by a dairy questionnaire in young Dutch adults. J Nutr 1996;126(11):2843–2850.
Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med 2000;154(6):610–613.
Specker B. Are activity and diet really important for children’s bones? Nutr Today 2002;37(2):44–49.
Zipfel S, Seibel MJ, Lowe B, et al. Osteoporosis in eating disorders: a followup study of patients with anorexia and bulimia nervosa. J Clin Endocrinol Metab 2001;86(11):5227–5233.
Riggs BL, Khosla S, Melton LJ, III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23(3):279–302.
Riggs BL, Khosla S, Melton LJ, III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13(5):763–773.
Stenson WF, Newberry R, Lorenz R, et al. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005;165(4):393–399.
Crawford BAL, Kam C, Donaghy AJ, et al. The heterogeneity of bone disease in cirrhosis: a multivariate analysis. Osteoporos Int 2003;14(12):987–994.
Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43(3):566–571.
Bilezikian JP. Primary hyperparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. MJ Favus (ed). Washington, DC: American Society for Bone and Mineral Research, 2003.
Cock TA, Auwerx J. Leptin: cutting the fat off the bone. Lancet 2003;362(9395):1572–1574.
Heaney RP. Constructive interactions among nutrients and bone-active pharmacologic agents with principal emphasis on calcium, phosphorus, vitamin D and protein. J Am Coll Nutr 2001;20(5 Suppl):403S–409S.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142(12):5050–5055.
Jorgensen HL, Kusk P, Madsen B, et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab 2004;22(2):132–138.
Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346(20):1513–1521.
Nevitt MC, Cummings SR, Hudes ES. Risk factors for injurious falls: a prospective study. J Gerontol 1991;46(5):M164–M170.
Nelson HD, Helfand M, Woolf SH, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137(6):529–541; appendix E-541-E-543.
Binkley NC, Schmeer P, Wasnich RD, et al. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom 2002;5(Suppl):S19–S27.
Kanis JA, Melton LJ, III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137–1141.
Leib ES, Lewiecki EM, Binkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004;7(1):1–6.
Hamdy RC, Petak SM, Lenchik L. Which central dual x-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom 2002;5(Suppl):S11–S17.
Greenspan SL, von Stetten E, Emond SK, et al. Instant vertebral assessment: a noninvasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001;4(4):373–380.
Grampp S, Genant HK, Mathur A, et al. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res 1997;12(5):697–711.
Frost ML, Blake GM, Fogelman I. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int 2000;11(4):321–330.
Pistoia W, Van Rietbergen B, Lochmuller EM, et al. Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from “bench” to “bedside.” J Clin Densitom 2004;7(2):153–160.
Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87(10):4431–4437.
Looker AC. The skeleton, race, and ethnicity [editorial]. J Clin Endocrinol Metab 2002;87(7):3047–3050.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes FaNBIoM. Dietary Reference Intakes for Calcium, Phosphorous, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academies Press, 1997.
Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167(10 Suppl):S1–S34.
Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80(6 Suppl):1706S–1709S.
Heaney RP, Dowell MS, Bierman J, et al. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001;20(3):239–246.
U.S. Department of Agriculture, U.S. Department of Health and Human Services. Dietary Guidelines for Americans 2005. Washington, DC: U.S. Government Printing Office, 2005.
Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004;292(1):65–74.
Beck BR, Snow CM. Bone health across the lifespan—exercising our options. Exerc Sport Sci Rev 2003;31(3):117–122.
Leblanc AD, Schneider VS, Evans HJ, et al. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 1990;5(8):843–850.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282(7):637–645.
Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85(11):4118–4124.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344–1352.
Austin PC, Mamdani MM, Tu K, et al. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women’s Health Initiative Study. JAMA 2003;289(24):3241–3242.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321–333.
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343(9):604–610.
Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15(6):1006–1013.
Chow CC, Chan WB, Li JKY, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88(2):581–587.
Uusi-Rasi K, Sievanen H, Heinonen A, et al. Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-month follow-up of a randomized, controlled trial. Bone 2004;35(3):799–805.
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Tech Rep Ser 1994;843:1–129.
Rosen CJ, Black DM, Greenspan SL. Vignettes in osteoporosis: a road map to successful therapeutics. J Bone Miner Res 2004;19(1):3–10.
Schousboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142(9):734–741; appendix W-157-W-163.
Kanis JA, Black D, Cooper C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13(7):527–536.
Pak CYC, Zerwekh JE, Antich P. Anabolic effects of fluoride on bone. Trends Endocrinol Metab 1995;6(7):229–234.
Reginster JY. Treatment of postmenopausal osteoporosis. BMJ 2005;330(7496):859–860.
Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33(3):301–307.
Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294–1301.
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653–661.
Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005;23(8):1644–1655.
Chesnut CH, III, Silverman S, Andriano K, et al. Arandomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109(4):267–276.
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459–468.
Sugiyama M, Kodama T, Konishi K, et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;271(3):688–692.
Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164(2):146–152.
Rejnmark L, Olsen ML, Johnsen SP, et al. Hip fracture risk in statin users—a population-based Danish case-control study. Osteoporos Int 2004;15(6):452–458.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434–1441.
Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207–1215.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Bellantoni, M.F. (2006). The Medical Management of Bone Health and Osteoporosis. In: Mathis, J.M., Deramond, H., Belkoff, S.M. (eds) Percutaneous Vertebroplasty and Kyphoplasty. Springer, New York, NY . https://doi.org/10.1007/0-387-36083-2_3
Download citation
DOI: https://doi.org/10.1007/0-387-36083-2_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-29078-2
Online ISBN: 978-0-387-36083-6
eBook Packages: MedicineMedicine (R0)